Original Publication Date: 14 March, 2016
Publication / Source: Immunotherapy
Authors: Buonaguro FM, Buonaguro L
Hepatocellular carcinoma (HCC) is the third and the fifth leading cause of death from cancer globally in men and women, respectively. The overall prognosis for HCC patients is poor, with a dismal 5-year survival rate of approximately 5–6%. The majority of patients are diagnosed when disease can be treated only with locoregional therapies resulting in limited survival benefits and tumor recurrence in 50–80% of patients at 5 years after treatment .